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regimen. Randomization to a new oral antithrombotics was associated with a significantly
increased risk of major bleeding (OR, 1.99; 95% CI, 1.65 to 2.39).
Conclusions: In patients with ACS, the addition of new oral antithrombotic agent to
standard antiplatelet therapy significantly reduced the primary composite end point but
significantly increased the risk of major bleeding.
TCT-715
First Demonstration of dose Dependent Effect of Statin Therapy on Urinary
11-dehydrothromboxane B2 levels in Patients Undergoing Coronary
Angiography
Anand Singla1, Kevin Bliden2, Peter Toth3, Udaya Tantry2, Young-Hoon Jeong4,
Ali Tabrizchi2, Denny Mathew2, Gordon Ens5, Paul Gurbel2
1Guthrie Robert Packer Hospital, Sayre, PA, 2Sinai Center for Thrombosis
Research, Baltimore, MD, 3University of Illinois College of Medicine, Peoria, IL,
4Sinai Hospital in Baltimore, Baltimore, MD, 5Creative Clinical Concepts, Inc,
Andover, KS
Background: Aspirin and statin therapy are primary treatment strategies in patients with
cardiovascular disease. Heightened urinary 11-dehydrothromboxane B2(11-dTxB2) lev-
els have been associated with an increased risk of adverse cardiovascular events. The aim
of the study was to determine the effect of statin therapy on 11-dTxB2 levels in patients
undergoing coronary angiography on 325 mg aspirin.
Methods: Urinary 11-dTxB2 was measured in patients prior to coronary angiography
with (n155) and without (n95) statin therapy. Lipoproteins by vertical density gradient
ultracentrifugation technique and thrombin-induced platelet-fibrin clot strength(TIP-FCS),
a marker for cardiovascular events by thrombelastography, were also measured. The dose
dependent effect of statin therapy was analyzed according to atorvastatin equivalent dose,
categorized as: 5-10mg, 20-40mg, 80mg.
Results: Baseline demographics and cardiac risk factors were similar between groups.
Statins significantly reduced urinary 11-dTxB2 levels in a dose dependent manner
(Figure). There was a significant relation between quartiles of 11-dTxB2 and TIP-
FCS,(p0.05 for ANOVA). Patients on statin therapy had significantly lower levels of
LDL, triglycerides, VLDL, atherox and apo B100 (p0.005 for all). However, Urinary
11-dTxB2 did not correlate with lipids and lipoproteins measurements.
Conclusions: This is the first study to demonstrate the dose dependent response of statin
therapy on urinary 11-dTxB2 levels, independent of lipid lowering effects.Clinical
outcome studies are required to determine the utility of this novel marker for optimizing
statin therapy.
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Background: Fish Oil supplementation may have anti-atherosclerotic effects by reducing
triglycerides, improving endothelial function, and reducing inflammation. However,
inconsistent results have been reported on the effects of fish oil on platelet function. We
aimed to determine if fish oil supplementation reduced the atherothrombotic risk profile
by measuring lipids and thrombogenic factors simultaneously.
Methods: Patients with suspected coronary artery disease with (n79) and without
(n324) fish oil supplementation were enrolled in the Multi-Analyte, Thrombogenic, and
Genetic Markers of Atheroclerosis (MAGMA) study. The lipid profile was determined by
vertical density gradient ultracentrifugation technique, and thrombogenicity by thrombe-
lastography immediately prior to elective coronary angiography. Urinary 11-
dehydrothromboxane B2 and AtherOx were performed by immunoassay. ADP and collagen-
induced platelet aggregation were measured in aspirin	 clopidogrel- treated patients.
Results: Baseline demographics and cardiac risk factors were similar between groups.
Fish oil supplementation was associated with significantly lower triglycerides, VLDL,
remnant lipoproteins, and AtherOx levels and increased HDL levels (p0.05). Among
patients on aspirin 	 clopidogrel therapy, fish oil supplementation was associated with
lower collagen-induced platelet aggregation (p0.05, Table).
No Fish Oil
(n324)
Fish Oil
(n79)
p-valueMean  SD Mean SD
Lipid Profile (mg/dL)
Total cholesterol 16138 16252 0.85
Total low density lipoprotein 9330 9443 0.87
Total high density lipoprotein 4412 4917 0.03
Total very low density lipoprotein 2213 196 0.02
Triglycerides 12690 10357 0.05
Remnant lipoproteins 24.311 21.07.6 0.02
Thrombogenicity Profile
AtherOx (mg/dL) 0.420.48 0.290.27 0.05
Lipoprotein (a) (mg/dL) 8.66.3 8.46.0 0.82
11-dehydrothromboxane B2 (pg/
mg creatinine)
16331636 13301520 0.25
Clotting index 0.72.6 0.53.2 0.12
MAKH (mm) 66.66.1 65.54.5 0.21
R (min) 7.92.3 7.42.9 0.12
20uM ADP-induced aggregation 5220 4621 0.2
4ug/mL collagen-induced
aggregation
4822 3822 0.05
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